Clinical trials
Chronic Myeloid Leukemia, Chronic Phase clinical trials
Below are recruiting chronic myeloid leukemia, chronic phase clinical trials, each written for real people, not researchers. We’re tracking 121 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06448013RecruitingPhase 1
Ziftomenib with chemo for pediatric AML
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
Houston, TexasAges 3–21 - NCT06746519RecruitingPhase 1/Phase 2
BN104 combined with chemotherapy or targeted therapy for AML
This clinical trial tests a new menin-blocking drug called BN104 in combination with chemotherapy or other targeted drugs for people with acute myeloid leukemia (AML) that has certain genetic changes. It may be an option if your AML is newly diagnosed or if you've already tried a menin inhibitor and it didn't work well enough.
Suzhou, JiangsuAges 18 years+ - NCT06824168RecruitingPhase 2
Quizartinib maintenance for FLT3-ITD AML in remission
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
Baltimore, MarylandAges 18 years+ - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT07623616RecruitingPhase 2
Ziftomenib for relapsed AML with NPM1 mutation
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
ChibaAges 18 years+ - NCT06532058RecruitingPhase 2
Study of a new drug for relapsed or hard-to-treat acute myeloid leukemia
This trial tests an experimental drug called QHRD107 combined with other medicines for people whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The goal is to see if the new combination is safe and helps control the leukemia.
Zhengzhou, HenanAges 18 years+ - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Phoenix, ArizonaAges 18 years+ - NCT05360160RecruitingPhase 1/Phase 2
Oral menin inhibitor plus AML medicines for new or relapsed AML
This trial tests an all-pill (oral) combination treatment—menin inhibitor SNDX-5613 plus decitabine/cedazuridine (ASTX727) and venetoclax—for acute myeloid leukemia (AML). It’s designed for people who are newly diagnosed and can’t get the strongest chemotherapy, or for certain other AML groups who may still benefit.
Houston, TexasAges 12 years+ - NCT06191978RecruitingPhase 1
Testing venetoclax with decitabine/cedazuridine for pediatric AML
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
Houston, TexasAges 2–18 - NCT06549790RecruitingPhase 1
Study of NMS-03597812 for relapsed or refractory AML
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT05584761RecruitingPhase 1/Phase 2
Cord blood stem cells plus azacitidine for advanced blood cancers
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Nanjing, JiangsuAges 18–80 - NCT05834244RecruitingPhase 1
New and relapsed AML treatment using azacitidine, venetoclax, and NK cells
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
Cleveland, OhioAges 18 years+ - NCT04769947Recruiting
Registry for CML patients in deep remission after stopping pills
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
TurinAges 18 years+ - NCT05605379Recruiting
Study of how children with CML respond to first TKI treatment
This trial looks at how well children with chronic myeloid leukemia (CML) respond to standard “TKI” tablets when treatment starts. It uses genetic test results from diagnosis (DNA/RNA) to understand which children respond better and why.
BordeauxAges 6–18 - NCT06130787Recruiting
Using your body's age to personalize CML treatment
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
AnnecyAges 18 years+ - NCT02889003RecruitingPhase 2
Second attempt to stop treatment after pioglitazone in CML
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
Le ChesnayAges 18 years+ - NCT06765876RecruitingEarly Phase 1
CAR T-cell therapy for CD123+ blood cancers
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called CD123 on cancer cells. It is for people with certain blood cancers (AML, MDS-IB2, BPDCN, or ALL) that have come back or not responded to other treatments.
PragueAges 18–70 - NCT05732103RecruitingPhase 1/Phase 2
Testing CTX-712 for AML or high-risk MDS after prior treatment
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Phoenix, ArizonaAges 18 years+ - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+ - NCT07514832RecruitingPhase 2
New chemotherapy combination for untreated acute myeloid leukemia
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
BeijingAges 18–70 - NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Duarte, CaliforniaAges 4 weeks+ - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for certain relapsed blood cancers
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
Mankato, MinnesotaAges 18 years+
Hear when a new Chronic Myeloid Leukemia, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic myeloid leukemia, chronic phase?
- Yes. Clin2 currently lists 121 recruiting chronic myeloid leukemia, chronic phase studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic myeloid leukemia, chronic phase trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic myeloid leukemia, chronic phase trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.